secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K/A
Filed at:   2026-07-30T10:02:24+00:00
Accession:  0001193125-26-324786
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics files Orphai acquisition financials; pipeline details disclosed
--------------------------------------------------------------------------------

- Audited Orphai financials for FY2024-2025 and unaudited Q1 2026 now filed; pro forma combined financials included.
- Lead asset LAM-001 (inhaled rapamycin) targets PH-ILD, BOS, and SAPH; Phase 2b PH-ILD data expected Q1 2028.
- Phase 2 BOS trial fully enrolled, preliminary data expected Q1 2027; SAPH Phase 2 to start late 2026.
- Acquisition funded by $115M upfront private placement; potential additional $83M from warrant exercises.
- Orphai's former COO Keith Fandrick joins as Head of Technical Operations; Brigette Roberts remains Chief Corporate Affairs Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526324786/0001193125-26-324786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526324786/d163930d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-324786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer